Ticker brief · 2026-07-03
HIMS HIMS & HERS HEALTH INC
Peptide optionality and breakout momentum dominate HIMS debate
Communications · Internet
Lean: bullishlast close
$36.80
1 day
-2.0%
14 days
+3.7%
mkt cap
$8.5B
signals 14d
857
authors 14d
203
The tape is bullish, with credible upside voices clustering around FDA peptide optionality, Q2 reacceleration, technical breakouts, and sell-side target raises. The late-week shift was from pure retail momentum into institutional validation: Canaccord, BofA, Barclays and Needham all entered the discussion, while David Wells bought 48,000 shares at $24.24 and HIMS announced a $400M JPM receivables facility. Trade structure is crowded upside optionality, not a clean fundamental long: much of the near-term move depends on July 23-24 peptide framing and whether the 200DMA breakout holds.
BULL CAMP
Bulls argue HIMS has moved from hated GLP-1 panic name to reaccelerating consumer-health platform with peptide optionality, stronger app and MAU data, insider validation, and a technical setup targeting the $40s and above. The strongest credible bulls are not all clean: several active supporters have negative trader_score_20, but the bull camp still has higher-quality support than the bear camp.
Key voices@JonahLuptonMEDIUM-HIGHA+1.14@alc2022MEDIUM-HIGHC+1.21@TheStockerManMEDIUMB+3.05@pdicarlotraderMEDIUM-HIGHC+1.45
BEAR / SKEPTIC
Bears focus on the FDA staff proposal to keep 7 peptides off the 503A Bulks List, lack of a near-term 503B pathway, valuation ceilings, and GLP-1 competitive pressure from branded access programs. The bear camp is thinner and more fragmented, with fewer high-credibility voices and less repeated evidence than the bull camp.
Key voices@ConsensusGurusMEDIUM-HIGHB+1.10@sp3cul8rMEDIUM-HIGHB-0.28@EhrmantrautCap_MEDIUMC+1.46@SixSigmaCapitalMEDIUM-HIGHB-0.48
“Questions whether HIMS is impaired if peptides are no longer viable”— @ConsensusGurus · tweet ↗
Hypotheses14direction · basis · magnitude · supporters — NEW = first seen this week
▲FDA and HHS peptide panel changes could improve odds that peptide compounding remains available to HIMS after July 23-24.
@himshouseLOW-MEDIUMC+2.909s@Investinc_IntelLOW-MEDIUMC+0.282s@MisterInversorMEDIUMC-0.572s@TheLongInvestMEDIUM-HIGHC-2.161s@JJrit1816LOW-MEDIUMC+0.852s@JonahLuptonMEDIUM-HIGHA+1.141s · insight+3 more
▼FDA staff opposition to 7 peptides and no near-term 503B path could impair HIMS peptide upside.
@himshouseLOW-MEDIUMC+2.904s@ConsensusGurusMEDIUM-HIGHB+1.101s · insight@sp3cul8rMEDIUM-HIGHB-0.281s · insight@AIStockSavvyMEDIUMC+0.051s
▲GLP-1 and peptide demand is underpenetrated, and insurance pullback could push cash-pay users toward HIMS.
@himshouseLOW-MEDIUMC+2.903s@JJrit1816LOW-MEDIUMC+0.852s@TheStockerManMEDIUMB+3.052s@Arturraposo1RLOW-MEDIUMB-0.452s@AlphaOwlTradingLOW-MEDIUMC+1.701s@donaldjdeanMEDIUMC+0.621s+1 more
▲HIMS deserves a platform re-rating as a D2C healthcare, AI, data and recurring-revenue business rather than a GLP-1 trade.
@alc2022MEDIUM-HIGHC+1.219s@CMDarnton0LOW-MEDIUMC-0.442s@MisterInversorMEDIUMC-0.575s@TheStockerManMEDIUMB+3.053s@TheRealBirnbaumLOW-MEDIUMC+2.113s@growthrapidlyMEDIUMC-3.002s+2 more
▲Q2 and alternative data show HIMS demand reaccelerating, supporting guidance upside and a validation event into earnings.
@himshouseLOW-MEDIUMC+2.903s@growthrapidlyMEDIUMC-3.005s@TheStockerManMEDIUMB+3.051s@invertiramateurMEDIUM-HIGHB-0.751s · insight@DrTomsLensLOW-MEDIUMC+0.981s@MatiasManuel71LOW-MEDIUMB+1.251s
▲HIMS has reclaimed key moving averages and broken resistance, opening a technical path toward $40-$55 or higher.
@TheLongInvestMEDIUM-HIGHC-2.168s@Fibonacci_TAMEDIUMC-0.199s@Arturraposo1RLOW-MEDIUMB-0.455s@pdicarlotraderMEDIUM-HIGHC+1.455s@TheValueTradeMEDIUMC+1.951s@SRxTradesMEDIUM-HIGHC+0.352s+4 more
▲High short interest, scarce borrow and call-ladder activity could force a squeeze toward $40 and beyond.
@himshouseLOW-MEDIUMC+2.903s@Fibonacci_TAMEDIUMC-0.193s@salmaogsMEDIUM-HIGHC3s@RockyTSTHLOW-MEDIUMC1s@GassionGretaMEDIUMC+0.401s@Arturraposo1RLOW-MEDIUMB-0.452s+2 more
▲Sell-side target raises and notes from Canaccord, BofA, Barclays and Needham validate improving HIMS fundamentals.
@himshouseLOW-MEDIUMC+2.905s@Investinc_IntelLOW-MEDIUMC+0.283s@TheLongInvestMEDIUM-HIGHC-2.161s@AlphaOwlTradingLOW-MEDIUMC+1.702s@EmmanuelInvestLOW-MEDIUMC-1.121s@TipRanksHIGHC1s+3 more
▲David Wells first insider buy in years signals board-level confidence in HIMS after GLP-1 panic.
@himshouseLOW-MEDIUMC+2.903s@EmmanuelInvestLOW-MEDIUMC-1.122s@DrTomsLensLOW-MEDIUMC+0.981s@BastianelliLoreMEDIUMA+2.041s · insight
▲The $400M JPM receivables facility improves HIMS liquidity and cash-flow flexibility rather than signaling distress.
@himshouseLOW-MEDIUMC+2.901s@Investinc_IntelLOW-MEDIUMC+0.281s@EmmanuelInvestLOW-MEDIUMC-1.121s@JJrit1816LOW-MEDIUMC+0.851s@Arturraposo1RLOW-MEDIUMB-0.451s@Chill_InvestingLOW-MEDIUMC+0.301s
▲Capital is rotating from crowded AI and memory winners into undervalued healthcare names, including HIMS.
@Arturraposo1RLOW-MEDIUMB-0.456s@TheStockerManMEDIUMB+3.052s@TrendSpiderMEDIUM-HIGHC-0.581s@NighthawkTradezLOW-MEDIUMC+1.241s@TheProfInvestorMEDIUM-HIGHC+0.271s@Kev_Capital_TALOW-MEDIUMC+0.591s+1 more
▼HIMS faces valuation ceilings, industry resistance, branded GLP-1 competition and payment concerns that could cap upside.
@CyberCabDavidLOW-MEDIUMC+0.841s@EhrmantrautCap_MEDIUMC+1.461s@SixSigmaCapitalMEDIUM-HIGHB-0.481s · insight@himshouseLOW-MEDIUMC+2.902s@MatiasManuel71LOW-MEDIUMB+1.251s@TheRealBirnbaumLOW-MEDIUMC+2.111s
◆Some holders are trimming, selling calls or using 200DMA loss as an exit trigger after the sharp rebound.
@EchoAnalysisMEDIUMC+0.384s@Money_or_Life_XMEDIUMB+1.913s · insight@optionscjpMEDIUMC-3.191s@yianiszMEDIUM-HIGHA+0.531s · insight@Markadiusz45LOW-MEDIUMC-2.901s@Maximus_HollaLOW-MEDIUMC-0.481s
◆A concentrated single-author thesis frames HIMS as a healthcare ontology worth $2,000/share by 2030.
@alc2022MEDIUM-HIGHC+1.211s
Direct calls5authors taking explicit directional positions
@TheLongInvestMEDIUM-HIGHC-2.16
HIMS is going to $40 next for Wave 3
@RevSharkHIGHB+2.42
HIMS is top radar name for a run into earnings and July peptide conference
@pdicarlotraderMEDIUM-HIGHC+1.45
Plans to buy HIMS as bull cycle starts
@sp3cul8rMEDIUM-HIGHB-0.28
HIMS will likely take a hit tomorrow
@alc2022MEDIUM-HIGHC+1.21
Buy as much HIMS and DUOL as possible
Sellside activity6
Canaccord pt_raise PT 40 (from 32)Raised HIMS price target to $40 from $32 with Buy rating
Bank of America pt_raise PT 36 (from 25)Raised HIMS target to $36 from $25 while maintaining Hold
Barclays noteSaid HIMS/Hers MAU rose 21% m/m in May and GLP-1 business is reaccelerating
Needham noteAnalyst still expects peptides under review to be approved despite FDA briefing document
BofA note PT 36 (from 25)Maintains Neutral but raises target to $36 from $25 while calling FDA update negative
Canaccord reiterate PT 40 (from 32)Maintained Buy and raised target to $40 from $32
News / data points5discrete events + data quoted by authors
@himshouseLOW-MEDIUMC+2.90
David Wells bought 48,000 HIMS shares at $24.24, about $1.2M
@Investinc_IntelLOW-MEDIUMC+0.28
HIMS entered a $400M receivables deal with JPM to improve cash flow
@himshouseLOW-MEDIUMC+2.90
Barclays said HIMS/Hers MAU rose 21% m/m in May and GLP-1 is reaccelerating
@himshouseLOW-MEDIUMC+2.90
FDA proposed adding none of 7 peptides to the 503A Bulks List; PCAC meets July 23-24
@Fibonacci_TAMEDIUMC-0.19
Options grid repriced higher with $1.96M calls at $40 for January and floor $33
Position disclosures3skin in the game
@growthrapidlyMEDIUMC-3.00
4,000+ HIMS shares, cost around $28, with long-term $1M+ profit belief
@MisterInversorMEDIUMC-0.57
HIMS is 28% of portfolio after earlier 25% disclosure
@JJrit1816LOW-MEDIUMC+0.85
HIMS position exceeded 70%
Desk readconvergence assessment
The view is directionally converged bullish, but the convergence is built around two unstable pillars: July 23-24 peptide optionality and a technical momentum breakout. Credibility asymmetry favors the bulls because high and medium-high accounts appear in the bull camp, but several loud bulls have negative trader_score_20 or promotional framing, while the bear camp is smaller but points to a real regulatory contradiction. The view would change quickly if PCAC/FDA signals confirm no viable peptide path, app and transaction data fail to convert into Q2 upside, or the stock loses the 200DMA breakout that many traders use as their exit line.
Tracked hypotheses — caliber-scored view · 2026-06-22
🟢 HIGH caliber (5)
📈 h5 bull · score 0.82
Barclays' Overweight reiteration and $39 target raise validate the post-Novo growth reacceleration narrative.
- Supporters (8): @markflowchatter↗(MEDIUM-,1p), @zohmbastic↗(MEDIUM,1p), @himshouse↗(LOW-MED,2p), @TheLongInvest↗(MEDIUM-,1p), @yianisz↗(MEDIUM-,1p), +3
- Signals: 12 · Max author share: 0.22 · Novelty: building
- Quote: "Barclays raised the target to $39 from $29 and cited growth inflection after Novo." — zohmbastic
📈 h3 bull · score 0.79
A breakout through $30-$35 and the 200DMA opens a technical path toward $40-$46.
- Supporters (10): @FibonacciTA(MEDIUM,8p), @TheLongInvest↗(MEDIUM-,7p), @enrichtrades↗(MEDIUM,6p), @SRxTrades↗(MEDIUM-,2p), @MrDerivatives(MEDIUM-,2p), +5
- Signals: 18 · Max author share: 0.22 · Novelty: building
- Quote: "Break above 200DMA at $33.40 leaves little resistance to the $41 target." — TheLongInvest
📈 h2 bull · score 0.75
Peptides, GLP-1 demand, and Novo/Wegovy distribution can drive a major revenue step-up for HIMS.
- Supporters (10): @JJrit1816↗(LOW-MED,4p), @himshouse↗(LOW-MED,10p), @TheDrugMoney↗(LOW-MED,4p), @data168↗(MEDIUM-,3p), @TheStockerMan↗(MEDIUM,2p), +5
- Signals: 16 · Max author share: 0.34 · Novelty: building
- Quote: "HIMS Zava is selling Wegovy pill in the UK, expanding branded GLP-1 access." — himshouse
📈 h1 bull · score 0.68
HIMS can re-rate as a consumer healthcare front door with subscriptions, AI, personalization, data, and longitudinal care expanding lifetime value.
- Supporters (10): @CMDarnton0↗(LOW-MED,3p), @MisterInversor↗(MEDIUM,8p), @harry03994688↗(LOW-MED,1p), @JonahLupton↗(MEDIUM-,1p), @alc2022↗(MEDIUM-,5p), +5
- Signals: 12 · Max author share: 0.31 · Novelty: stable
- Quote: "HIMS has a consumer health data loop that can improve adherence, pharma value, and lifetime care." — CMDarnton0
📈 h4 bull · score 0.53
High short interest, call accumulation, and crowded bearish positioning can force a squeeze if catalysts keep arriving.
- Supporters (10): @yianisz↗(MEDIUM-,3p), @DrStoxx↗(MEDIUM-,1p), @JJrit1816↗(LOW-MED,1p), @data168↗(MEDIUM-,2p), @salmaogs↗(MEDIUM-,3p), +5
- Signals: 14 · Max author share: 0.18 · Novelty: stable
- Quote: "Key support-resistance flip plus roughly 30% short float creates upside squeeze risk." — DrStoxx
🟡 MEDIUM caliber (4)
📈 h6 bull · score 0.82
Oura and native wearable data sync can expand HIMS from telehealth into a broader AI health platform.
- Supporters (10): @himshouse↗(LOW-MED,2p), @NighthawkTradez↗(LOW-MED,3p), @AlphaOwlTrading↗(LOW-MED,1p), @MisterInversor↗(MEDIUM,2p), @StockSavvyShay↗(HIGH,1p), +5
- Signals: 12 · Max author share: 0.20 · Novelty: new
- Quote: "CEO said wearable sync is coming soon, showing progress toward an AI health platform." — StockSavvyShay
📉 h11 bear · score 0.51
GLP-1 and partnership risks remain unresolved, including FDA scrutiny, compounded-drug concerns, and Novo alliance quality.
- Supporters (5): @OracleNYSE↗(MEDIUM,1p), @RentYourStocks↗(LOW-MED,1p), @Stevendiaz↗(MEDIUM,1p), @AponiaAnalytics↗(LOW-MED,1p), @data168↗(MEDIUM-,1p)
- Signals: 5 · Max author share: 0.20 · Novelty: building
- Quote: "FDA warned telehealth companies over compounded GLP-1s, keeping regulatory risk in focus." — OracleNYSE
📉 h10 bear · score 0.36
HIMS may be overextended, cult-like, or inflated after the rebound, making risk-reward less attractive.
- Supporters (7): @BastianelliLore↗(MEDIUM,1p), @AparicioCadiz↗(MEDIUM,1p), @PhotonBull↗(MEDIUM,1p), @DGrettaAuthor(LOW-MED,1p), @FibonacciTA(MEDIUM,1p), +2
- Signals: 8 · Max author share: 0.25 · Novelty: building
- Quote: "The discourse has become unhealthy and cult-like after the rally, so caution is warranted." — BastianelliLore
↔️ h9 neutral · score 0.30
After the violent rally into $33-$40 resistance, disciplined traders should trim rather than chase.
- Supporters (7): @FibonacciTA(MEDIUM,2p), @EchoAnalysis↗(MEDIUM,3p), @MaximusHolla(LOW-MED,1p), @pdicarlotrader↗(MEDIUM-,2p), @zohmbastic↗(MEDIUM,2p), +2
- Signals: 13 · Max author share: 0.25 · Novelty: building
- Quote: "Taking profits between $33 and $40 is acceptable after the breakout." — Fibonacci_TA
⚪ LOW caliber (2)
📈 h7 bull · score 0.36
App rankings, traffic, alt data, and category demand suggest Q2 revenue can beat conservative expectations.
- Supporters (7): @Investinc_Intel↗(LOW-MED,4p), @himshouse↗(LOW-MED,4p), @YodaStockInvest↗(MEDIUM,1p), @BastianelliLore↗(MEDIUM,1p), @TheStockerMan↗(MEDIUM,1p), +2
- Signals: 9 · Max author share: 0.31 · Novelty: stable
- Quote: "Alt data is strongest in more than twelve months and supports a Q2 revenue prediction." — himshouse
📈 h8 bull · score 0.15
Management execution, insider alignment, and shareholder-friendly signals reduce governance concerns after prior CEO-sale criticism.
- Supporters (5): @Investinc_Intel↗(LOW-MED,3p), @himshouse↗(LOW-MED,1p), @CEOStockWatcher↗(MEDIUM,1p), @TheRealBirnbaum↗(LOW-MED,1p), @Arturraposo1R↗(LOW-MED,1p)
- Signals: 7 · Max author share: 0.43 · Novelty: stable
- Quote: "Defends CEO alignment against the share-sale narrative and highlights ownership." — Investinc_Intel
🔴 FLAGGED caliber (1)
⚠️ h12 flag · score 0.16
Single-author hyperbolic targets of $1000-$2000 signal promotional excess rather than a broadly validated valuation case.
- Supporters (5): @alc2022↗(MEDIUM-,3p), @CMDarnton0↗(LOW-MED,4p), @NighthawkTradez↗(LOW-MED,1p), @TheDrugMoney↗(LOW-MED,1p), @Cantal_Capital↗(LOW-MED,1p)
- Signals: 10 · Max author share: 0.40 · Novelty: building
- Quote: "Claims HIMS has $2,000 per share intrinsic value by 2030." — alc2022
Sentiment — last 14 days
daily mean sentiment, 2026-06-19 → 2026-07-03 · now +0.38 (−1 bearish … +1 bullish)
Who spoke203
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Investinc_Intel | C | +0.28 | 60 | +0.51 |
| @himshouse | C | +2.90 | 59 | +0.29 |
| @MisterInversor | C | -0.57 | 52 | +0.55 |
| @Arturraposo1R | B | -0.45 | 42 | +0.47 |
| @JJrit1816 | C | +0.85 | 28 | +0.40 |
| @growthrapidly | C | -3.00 | 28 | +0.58 |
| @TheLongInvest | C | -2.16 | 27 | +0.51 |
| @alc2022 | C | +1.21 | 24 | +0.64 |
| @Fibonacci_TA | C | -0.19 | 23 | +0.50 |
| @NighthawkTradez | C | +1.24 | 21 | +0.53 |
| @TheStockerMan | B | +3.05 | 20 | +0.62 |
| @DrTomsLens | C | +0.98 | 15 | +0.52 |
| @YodaStockInvest | C | -0.01 | 12 | +0.65 |
| @EchoAnalysis | C | +0.38 | 12 | +0.02 |
| @AlphaOwlTrading | C | +1.70 | 11 | +0.48 |
| @TheValueTrade | C | +1.95 | 11 | +0.36 |
| @CMDarnton0 | C | -0.44 | 10 | +0.62 |
| @EmmanuelInvest | C | -1.12 | 10 | +0.30 |
| @TheRealBirnbaum | C | +2.11 | 10 | +0.59 |
| @Cantal_Capital | C | +0.49 | 9 | +0.58 |
| @JonahLupton | A | +1.14 | 8 | +0.57 |
| @BastianelliLore | A | +2.04 | 8 | +0.47 |
| @Chill_Investing | C | +0.30 | 8 | +0.36 |
| @StockChaser_ | C | +2.04 | 8 | +0.43 |
| @enrichtrades | C | -1.64 | 7 | +0.46 |
Recent signals30of 857 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-03 | @yianisz | -0.25 | Says HIMS bulls miss short interest fell from roughly 85M to 63-65M shares, 31% of float. | — | tweet ↗ |
| 2026-07-03 | @MacGillivrayCPA | +0.45 | Peptide market TAM and FDA compounding discussion framed as share opportunity for HIMS and ENHA. | — | tweet ↗ |
| 2026-07-03 | @aktien_max | +0.30 | Author says winners should run and discloses several holdings still in the portfolio. | — | tweet ↗ |
| 2026-07-03 | @Fibonacci_TA | +0.70 | Monthly chart bullish; support $28-$32 held opens road to $70. | — | tweet ↗ |
| 2026-07-03 | @MisterInversor | +0.75 | Discloses HIMS is the author's largest position for the second half. | — | tweet ↗ |
| 2026-07-03 | @Arturraposo1R | +0.35 | Says GLP-1 penetration is under 10% and likely won't stay that low given trial performance. | — | tweet ↗ |
| 2026-07-03 | @Arturraposo1R | +0.15 | Argues institutions shifted Nike narrative down to buy cheap shares and rerates are coming. | — | tweet ↗ |
| 2026-07-03 | @Arturraposo1R | +0.50 | Says HIMS, OSCR and NVO are all you need this year. | — | tweet ↗ |
| 2026-07-03 | @Markadiusz45 | +0.20 | Weekly portfolio recap with closed BIDU, derisked names, HIMS cut in half, and missed trades. | — | tweet ↗ |
| 2026-07-03 | @harry03994688 | +0.70 | Bullish thematic thesis on digital biology, GLP-1 distribution, and data/memory demand. | — | tweet ↗ |
| 2026-07-03 | @R1chardMaur1ce | +0.30 | Describes resistance at 37.50/41.50 and 40-60% upside if resistance flips to support. | — | tweet ↗ |
| 2026-07-02 | @d_pavlos | +0.35 | Recaps weekly focus-list performance and win rate after the move. | — | tweet ↗ |
| 2026-07-02 | @MacGillivrayCPA | +0.15 | Author will attend July 23 FDA meeting on recategorization of peptides; relevant peptide-exposed tickers listed. | — | tweet ↗ |
| 2026-07-02 | @TarekMM100 | +0.25 | Ticker with handshake emoji and chart, weak positive signal. | — | tweet ↗ |
| 2026-07-02 | @chad_ventures | +0.15 | Backtested system across 130+ names; says flagship profitable on roughly 95%, HIMS weekly attached. | — | tweet ↗ |
| 2026-07-02 | @TheRealBirnbaum | +0.85 | Long-term bullish HIMS thesis on scaling, healthcare TAM disruption, and founder vision. | — | tweet ↗ |
| 2026-07-02 | @TheRealBirnbaum | +0.85 | Says bear case for HIMS in 2030 is $200 per share. | — | tweet ↗ |
| 2026-07-02 | @MisterInversor | +0.65 | Lists stocks the author believes are very undervalued today. | — | tweet ↗ |
| 2026-07-02 | @Chill_Investing | +0.25 | Portfolio performance update with prices, RSI and company news across names. | — | tweet ↗ |
| 2026-07-02 | @AlphaOwlTrading | +0.45 | Frames obesity market as huge TAM for HIMS. | — | tweet ↗ |
| 2026-07-02 | @Investinc_Intel | +0.25 | Listen this time on SOFI — Author implies prior buy call on HIMS and now points to SOFI as next opportunity. | — | tweet ↗ |
| 2026-07-02 | @himshouse | +0.35 | Highlights large obesity market alongside HIMS ticker. | — | tweet ↗ |
| 2026-07-02 | @invertiramateur | +0.20 | Bought 1 DUOL share for a long-term weekly-buy portfolio. — Author reports new weekly purchase of DUOL with long-term thesis and price paid. | — | tweet ↗ |
| 2026-07-02 | @BabaNeal007 | +0.00 | Discloses giving back $41k in June while listing current tickers. | — | tweet ↗ |
| 2026-07-02 | @BastianelliLore | +0.20 | Lists learning-loop companies as a thematic basket. | — | tweet ↗ |
| 2026-07-02 | @TheStockerMan | +0.75 | Multi-year bullish thesis that HIMS can expand consumer healthcare categories and peptide optionality. | — | tweet ↗ |
| 2026-07-02 | @optionscjp | +0.25 | Sold rest of HIMS, still bullish, reports $150k total profit and buying from $18-$22. | — | tweet ↗ |
| 2026-07-02 | @TheStockerMan | +0.65 | Bullish HIMS platform thesis around peptides, FDA meeting, valuation, and NVO partnership. | — | tweet ↗ |
| 2026-07-02 | @MisterInversor | +0.55 | Says only patient and brave holders will go to Valhalla in HIMS. | — | tweet ↗ |
| 2026-07-02 | @TheProfInvestor | +0.45 | Calls for positioning in leading healthcare and banks amid rotation. | — | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.